Carrick Therapeutics, a company transforming cancer treatments by targeting the molecular pathways that drive the most aggressive and resistant forms of cancer, has acquired global licensing rights to develop and commercialise BTG's ovarian cancer drug BTG945, which has been renamed as CT900, it was reported on Friday.
The product is a targeted therapy that integrates targeting folate receptor and inhibiting thymidylate synthase.
In a phase one study led by The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust, presented at the American Society of Clinical Oncology Annual Meeting 2017, seven of ten women with advanced ovarian cancer who had the particular molecular marker for the drug responded to treatment. According to the contract with BTG, Carrick has received exclusive global development and commercialisation rights to CT900 and has already started preparations for pivotal studies. A clinical development programme in other cancers will also be undertaken.
Financial terms of the deal were not disclosed.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval